Company Overview and News


Add TECH
to your dashboard

Headline News

Robust Earnings Momentum Metrics Drive Upgrade of Bio-Techne (TECH) to Buy

2017-11-09 investorplace
Portfolio Grader currently ranks Bio-Techne Corp (NASDAQ:TECH) a Buy. Using Louis Navellier's investing approach, this analytical tool evaluates stocks by employing proprietary fundamental and quantitative analytical tools. The shares have been upgraded from a Hold to a Buy in the last week. (1-0)

Featured Company News - Japanese Patent Office Issued New Patent to Alexion Pharma's Soliris; Extending Patent Protection into 2027

2017-11-08 accesswire
LONDON, UK / ACCESSWIRE / November 8, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) ("Alexion"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=ALXN. The Company announced on November 06, 2017, that it has received a new Patent, directed to the composition of matter of eculizumab (Soliris®) and pharmaceutical formulations of eculizumabby Japanese Patent Office (JPO), which will expire in 2027. (56-0)

Bio-Techne (TECH) Q1 2018 Results - Earnings Call Transcript

2017-10-31 seekingalpha
Good morning and welcome to the Bio-Techne Earnings Conference Call for the First Quarter of Fiscal Year 2018. At this time, all participants have been placed in a listen-only mode, and the call will be opened for questions following management's prepared remarks. (1-0)

Is a Surprise Coming for Bio-Techne (TECH) This Earnings Season?

2017-10-30 zacks
Our experts cut down 220 Zacks Rank #1 Strong Buys to the 7 that are most likely to jump in price immediately. (2-0)

Bio-Techne To Host Conference Call On October 31, 2017 To Announce First Quarter 2018 Financial Results

2017-10-11 prnewswire
MINNEAPOLIS, Oct. 11, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call on October 31, 2017, at 8:00 a.m. CDT to review first quarter 2018 financial results. (1-0)

Joint Consortia Framework Awards Contract to Bio-Techne as Supplier of Research Antibodies

2017-10-05 prnewswire
LONDON, Oct. 5, 2017 /PRNewswire/ -- Bio-Techne has been selected as a  supplier of research antibodies under Lot 1: Antibodies of the Southern Universities Purchasing Consortium (SUPC), Antibodies and Sera Framework Agreement for the United Kingdom (UK) Higher Education Sector. (1-0)

Bio-Techne's New Simple Plex Cartridge Boosts Protein Segment

2017-09-28 zacks
A Bio-Techne Corporation (TECH - Free Report) brand, ProteinSimple, recently expanded the Ella immunoassay platform through the launch of a 32x4 Simple Plex cartridge. The cartridge provides more accurate results at a lower cost. Notably, ProteinSimple falls under the Protein Platforms division of Bio-Techne. (16-0)

Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength

2017-09-27 zacks
Luminex Corporation (LMNX - Free Report) , manufacturer and marketer of proprietary biological testing technologies with applications throughout the life sciences and diagnostics industry, is focusing on augmenting its portfolio strength through new FDA approvals. (36-0)

Bio-Techne Unveils A New Multi-Analyte Cartridge Format For The Ella Immunoassay Platform, Improving Sample Throughput

2017-09-20 devicespace
SAN JOSE, Calif., Sept. 20, 2017 /PRNewswire/ -- ProteinSimple®, a Bio-Techne brand, announced today an expansion of the Ella immunoassay platform with the launch of a 32x4 Simple Plex cartridge. This new cartridge simultaneously measures up to 32 different samples from serum, plasma, cell culture supernatants and other bodily fluids against four different analytes of interest. Doubling the current sample throughput while maintaining a total immunoassay time of 85 minutes, this new cartridge enables greater efficiency at a lower cost per reportable result. (1-0)

Bio-Techne Unveils a New Multi-Analyte Cartridge Format for the Ella™ Immunoassay Platform, Improving Sample Throughput

2017-09-20 prnewswire
SAN JOSE, Calif., Sept. 20, 2017 /PRNewswire/ -- ProteinSimple®, a Bio-Techne brand, announced today an expansion of the Ella immunoassay platform with the launch of a 32x4 Simple Plex™ cartridge. This new cartridge simultaneously measures up to 32 different samples from serum, plasma, cell culture supernatants and other bodily fluids against four different analytes of interest. Doubling the current sample throughput while maintaining a total immunoassay time of 85 minutes, this new cartridge enables greater efficiency at a lower cost per reportable result. (1-0)

GLOBAL WESTERN BLOTTING MARKET FORECAST 2017-2025

2017-09-19 prnewswire
LONDON, Sept. 19, 2017 /PRNewswire/ -- KEY FINDINGS The Global Western Blotting market is anticipated to generate $861 million at the end of 2025 by rising at a CAGR of 4.87%. The major drivers for this market include growing prevalence of HIV infections and the elaborate practice of this technique in proteomics. The fact that this market finds its applications in a wide range of areas is hugely aiding the market growth. (15-0)

Bio-Techne Introduces A New Luminex Multi-Analyte Assay Kit

2017-09-13 devicespace
MINNEAPOLIS, Sept. 13, 2017 /PRNewswire/ -- R&D Systems, a Bio-Techne brand, today announced the release of its new XL Cytokine Discovery Luminex® High Performance Panel.  As with all R&D Systems® Luminex Assays, this new panel is compatible with all Luminex instrumentation systems and has the capability to simultaneously measure the amount of 45 different analytes in a variety of sample types including cell culture supernate, serum, and plasma.

Bio-Techne Introduces a New Luminex Multi-analyte Assay Kit

2017-09-13 prnewswire
MINNEAPOLIS, Sept. 13, 2017 /PRNewswire/ -- R&D Systems, a Bio-Techne brand, today announced the release of its new XL Cytokine Discovery Luminex® High Performance Panel.  As with all R&D Systems® Luminex Assays, this new panel is compatible with all Luminex instrumentation systems and has the capability to simultaneously measure the amount of 45 different analytes in a variety of sample types including cell culture supernate, serum, and plasma.

Corporate News Blog - Exelixis Submits US Supplemental New Drug Application for CABOMETYX(R) for the Treatment of Previously Untreated Advanced Kidney Cancer

2017-08-18 accesswire
LONDON, UK / ACCESSWIRE / August 18, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Exelixis, Inc. (NASDAQ: EXEL) following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=EXEL. The Company announced on August 16, 2017, the submission of a supplemental New Drug Application (sNDA) to US Food and Drug Administration (FDA) for CABOMETYX® (cabozantinib) tablets as a treatment for patients with previously untreated advanced renal cell carcinoma (RCC).

Bio-Techne Declares Dividend

2017-08-11 devicespace
MINNEAPOLIS, Aug. 10, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2017. The quarterly dividend will be payable September 1, 2017 to all common shareholders of record on August 18, 2017. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

CUSIP: 09073M104